Masimo Receives FDA 510(k) Clearance for Root® With LiDCO® and LiDCO Sensor to Continuously Monitor Oxygen Delivery
Masimo, a Danaher company specializing in patient monitoring and diagnostic technologies, has received FDA 510(k) clearance for its Masimo Root® with LiDCO® hemodynamic monitoring solution, including the Masimo LiDCO Sensor. The newly cleared solution is designed to provide clinicians with the ability to continuously monitor and trend oxygen delivery, or DO₂, offering a more comprehensive view of how effectively oxygen is being transported to the body’s tissues.
The clearance expands the capabilities of Masimo’s patient monitoring portfolio by bringing together several measurements that are central to oxygen transport. These include continuous noninvasive hemoglobin monitoring through Masimo SpHb®, oxygen saturation measured with Masimo SET® pulse oximetry and cardiac output measured through LiDCO hemodynamic monitoring.
Together, these measurements can provide clinicians with a continuous view of oxygen delivery rather than requiring them to rely on intermittent laboratory measurements of hemoglobin.
The development is particularly relevant in high-risk surgical and critically ill patients, where changes in oxygen delivery can occur rapidly and where early recognition of inadequate oxygen supply may be important for clinical decision-making.
A More Complete View of Oxygen Delivery
Oxygen delivery represents the rate at which oxygen is transported from the lungs through the bloodstream to tissues throughout the body.
Several factors contribute to oxygen delivery, including the amount of blood being circulated and the amount of oxygen carried by that blood. Cardiac output provides information about how much blood the heart is pumping, while hemoglobin concentration and oxygen saturation help determine how much oxygen is available within the blood.
Historically, clinicians have not always had access to a continuous measurement that combines these factors into a single view of oxygen delivery.Hemoglobin has traditionally been measured through laboratory blood testing at specific intervals. While these measurements can provide valuable information, they do not continuously show how hemoglobin levels and oxygen delivery are changing between tests.
Masimo’s newly cleared solution is designed to address this gap by integrating continuous measurements from multiple monitoring technologies.By combining cardiac output, noninvasive hemoglobin and oxygen saturation, the system can continuously monitor and trend DO₂.This provides clinicians with an additional way to assess changes in oxygen transport during surgery, critical illness and other situations involving significant physiological stress.
Understanding the Role of DO₂ in Patient Care
Adequate oxygen delivery is fundamental to maintaining normal tissue and organ function.The body’s tissues require oxygen to produce energy and support essential cellular processes. When oxygen delivery does not meet tissue requirements, the resulting imbalance can contribute to physiological deterioration.
The concept of “oxygen debt” describes the cumulative difference between the amount of oxygen tissues require and the amount being delivered.When an oxygen deficit persists and is not corrected, it can contribute to serious complications, particularly in patients who are already physiologically vulnerable.
Research has examined the relationship between oxygen delivery and outcomes in high-risk surgical patients, with studies suggesting that DO₂ can serve as an actionable physiological target.This has made oxygen delivery an important area of interest in perioperative and critical care medicine.
Limitations of Intermittent Hemoglobin Testing
One of the challenges associated with assessing oxygen delivery has historically been the intermittent nature of hemoglobin measurements.A laboratory blood test provides a measurement at a particular moment. However, a patient’s physiological status can change considerably between laboratory tests.
Hemoglobin levels can be affected by factors such as bleeding, fluid administration and blood transfusion. At the same time, cardiac output and oxygen saturation can also change as a patient’s condition evolves.Because these variables can change at different rates, intermittent measurements may provide only a snapshot of a patient’s oxygen-carrying capacity.
Continuous monitoring can provide a different perspective by allowing clinicians to observe trends over time.Masimo’s integration of SpHb with oxygen saturation and cardiac output is intended to provide this continuous perspective.Rather than considering each measurement independently, clinicians can evaluate the combined information to better understand changes in oxygen delivery.
Integrating Hemoglobin, Oxygen Saturation and Cardiac Output
The Root with LiDCO solution combines several technologies within a single monitoring approach.Masimo SpHb is designed to provide noninvasive and continuous hemoglobin monitoring. Masimo SET pulse oximetry provides continuous oxygen saturation measurement, while LiDCO technology provides cardiac output monitoring.
Each of these measurements represents a different component of oxygen transport.Cardiac output reflects blood flow from the heart. Hemoglobin provides information about the blood’s oxygen-carrying capacity, while oxygen saturation indicates the proportion of hemoglobin carrying oxygen.
Bringing these measurements together can provide a more integrated assessment of oxygen delivery.The resulting DO₂ measurement is designed to help clinicians identify changes in oxygen supply and monitor how those changes develop over time.
Supporting High-Risk Surgical Patients
The clinical relevance of continuous oxygen delivery monitoring is particularly important in patients undergoing major surgery.Major surgical procedures can place substantial physiological demands on the body. Blood loss, changes in cardiac function, anesthesia, fluid administration and other factors can influence oxygen delivery.
High-risk patients may have limited physiological reserves, meaning that changes in oxygen transport could be especially important to recognize.Research has examined whether optimizing oxygen delivery around major surgery can influence outcomes.
According to Masimo, one randomized controlled trial involving 138 patients undergoing major elective surgery found that preoperative optimization of oxygen delivery was associated with a reduction in mortality from 17% in the control group to 3% among patients receiving preoptimization.
Another randomized trial involving 107 high-risk surgical patients evaluated a strategy of deliberately increasing oxygen delivery to a target above 600 mL/min/m² using dopexamine. The study reported a 75% reduction in 28-day mortality compared with standard perioperative care.
These studies highlight the clinical interest in using oxygen delivery as a target for managing high-risk patients.
However, monitoring oxygen delivery continuously can be challenging when one of its key components, hemoglobin, is traditionally obtained through intermittent laboratory testing.
Moving Toward Continuous Physiological Monitoring
Masimo’s new FDA-cleared solution reflects a broader movement toward continuous physiological monitoring.Traditional clinical monitoring often involves collecting individual measurements at different points in time. While these measurements remain important, continuous monitoring can offer additional information about trends and changes.
For clinicians, trends can be particularly valuable because a single measurement may not reveal whether a patient’s condition is improving, deteriorating or remaining stable.Continuous DO₂ monitoring is designed to allow healthcare professionals to observe oxygen delivery as it changes.
This could be useful during periods when a patient’s physiological status is changing rapidly, including major surgical procedures and critical care.By combining several measurements into an integrated view, the technology aims to reduce the need for clinicians to interpret multiple data points separately when assessing oxygen transport.
The Role of Blood Pressure and Cardiac Output
Blood pressure and cardiac output are commonly used to assess cardiovascular status, but they do not necessarily provide a complete picture of oxygen delivery.Blood pressure provides information about pressure within the circulatory system, while cardiac output provides information about blood flow.
As Dr. Basil Matta, Consultant in Critical Care, Affiliated Professor at the University of Cambridge and Chief Medical Officer at Masimo, explained, pressure is necessary for flow and flow is necessary to transport oxygen, but these measurements alone do not guarantee that tissues are receiving sufficient oxygen.This distinction is important because adequate blood pressure does not necessarily mean that tissue oxygen requirements are being met.
Similarly, cardiac output alone does not account for the amount of oxygen being carried by the blood.Hemoglobin and oxygen saturation provide additional information that can help determine the oxygen content of blood.By integrating these variables, Masimo’s approach is designed to provide clinicians with a broader understanding of oxygen transport.
Continuous Trend Monitoring
Another key capability of the newly cleared solution is the ability to trend oxygen delivery over time.Monitoring a single DO₂ value can provide information about a patient’s condition at a particular moment. Trending the measurement can provide additional insight into the direction of change.For example, clinicians may be able to observe whether oxygen delivery is increasing following an intervention or declining as a patient’s condition changes.
This information can potentially help healthcare teams evaluate the physiological effects of treatment and identify changes that may warrant further assessment.Continuous trends may also help clinicians understand the relationship between different physiological measurements.Changes in cardiac output, hemoglobin or oxygen saturation can each affect oxygen delivery. Monitoring them together can help provide context for why DO₂ is changing.
Expanding the Masimo Monitoring Portfolio
The FDA clearance adds another capability to Masimo’s existing patient monitoring technologies.
Masimo has developed monitoring technologies covering areas such as pulse oximetry, hemoglobin and other physiological parameters. The integration of LiDCO hemodynamic monitoring with these technologies extends the company’s ability to provide a more comprehensive view of patient physiology.
The Root platform serves as the foundation for bringing these measurements together.The company says the new capability represents part of its continued focus on developing technologies that can translate physiological information into clinically meaningful insights.As healthcare providers increasingly seek continuous and integrated monitoring solutions, combining multiple measurements into a unified platform could help streamline clinical assessment.
Potential Benefits During Physiological Stress
Patients undergoing major surgery or experiencing critical illness can encounter rapid changes in their physiological status.Blood loss can reduce hemoglobin levels. Changes in cardiac function can affect cardiac output. Respiratory or cardiovascular changes can influence oxygen saturation.Each of these factors can affect oxygen delivery.
When measurements are considered separately, clinicians may need to mentally integrate the information to determine how oxygen transport is changing.A continuous DO₂ measurement is intended to provide a more direct representation of oxygen delivery by incorporating these variables.This may help clinicians better understand the overall relationship between blood flow, oxygen-carrying capacity and oxygen saturation during periods of physiological stress.
Importance of Early Recognition
The concept of oxygen debt underscores why monitoring oxygen delivery can be clinically significant.When tissues receive less oxygen than they require, the resulting deficit can accumulate over time. If the underlying problem is not identified and addressed, prolonged oxygen deprivation may contribute to serious complications.
Research has linked persistent oxygen debt with conditions including organ dysfunction, sepsis and increased risk of death.For high-risk patients, identifying changes in oxygen delivery earlier may therefore be an important component of physiological management.
Continuous monitoring does not eliminate the need for clinical assessment or decision-making, but it can provide healthcare professionals with additional information about a patient’s changing physiological state.
FDA 510(k) Clearance
The FDA 510(k) clearance allows Masimo to market the Root with LiDCO hemodynamic monitoring solution, including the Masimo LiDCO Sensor, for its cleared indications.The regulatory milestone represents an expansion of the company’s capabilities in hemodynamic and patient monitoring.The combination of FDA-cleared technologies provides Masimo with an opportunity to offer clinicians a more integrated approach to monitoring oxygen delivery.
The company continues to focus on developing monitoring solutions that provide clinicians with information that can support patient management in demanding clinical environments.The introduction of continuous oxygen delivery monitoring marks another development in the evolution of patient monitoring technology.
For decades, clinicians have relied on individual physiological measurements to assess cardiovascular and respiratory status. Advances in continuous monitoring are increasingly allowing healthcare professionals to observe multiple parameters simultaneously and evaluate how they interact.
Masimo’s Root with LiDCO solution brings together cardiac output, noninvasive hemoglobin and oxygen saturation to provide continuous monitoring and trending of oxygen delivery.The approach is particularly relevant to high-risk surgical and critically ill patients, where changes in oxygen transport can have significant consequences.By providing continuous visibility into DO₂, the technology is intended to help clinicians better understand whether oxygen delivery is changing and how different physiological factors contribute to that change.
The FDA clearance also demonstrates the continued development of integrated monitoring platforms capable of bringing multiple measurements together.As healthcare increasingly moves toward continuous, data-driven patient monitoring, technologies that can provide a more comprehensive picture of physiological status may become increasingly valuable.
Masimo’s latest clearance expands the capabilities available through its monitoring portfolio and provides clinicians with another tool for evaluating oxygen transport during periods of physiological stress. By combining hemodynamic monitoring, noninvasive hemoglobin measurement and pulse oximetry, the company aims to give healthcare professionals a clearer and more continuous view of oxygen delivery when timely physiological information matters most.
Source link: https://www.masimo.com/
